Sector News

Cutispharma, Dr. Reddy's Laboratories announce partnership

April 6, 2016
Life sciences

CutisPharma, a specialty pharmaceutical company that has historically developed and distributed kits used by pharmacists to safely create compounded medications, announced today that it is entering into Active Pharmaceutical Ingredient (API) supply and joint development agreements with Dr. Reddy’s Laboratories Ltd. to advance several programs in CutisPharma’s R&D portfolio, including RM-02, RM-03, and RM-06, toward FDA approval.

“This partnership has significant strategic benefits for both parties,” said Neal Muni, MD, MSPH, Chief Executive Officer of CutisPharma. “Dr. Reddy’s Laboratories breadth of expertise and international infrastructure provide great synergy to CutisPharma’s own R&D and commercial organizations and will be a significant catalyst in our plans to fast-track the development of three of our programs towards New Drug Application (NDA) filings.”

Deepak Sapra, Vice President & Global Head, CPS Business of Dr. Reddy’s Laboratories, said “we continuously engage in research to find innovative solutions that address the unmet needs of patients and to create a robust healthcare ecosystem. The partnership with CutisPharma will further enhance and strengthen their R&D portfolio in bringing good health to millions in the country.”

“By leveraging the strengths of both parties, we look forward to expediting the development of three of our key R&D portfolio assets and maximizing commercial value of these programs in the United States as well as select international markets.” Muni said.

CutisPharma has aggressively invested in its research and development pipeline, recently announcing the opening of a state-of-the-art manufacturing center at its Wilmington, Mass., facility and completion of validation activities supporting its first NDA filing of the Company’s lead pipeline drug, RM-01, next year. The partnership with Dr. Reddy’s Laboratories will allow for the acceleration of three additional drugs, RM-02, RM-03 and RM-06, towards FDA approval.

Source: CutisPharma

Related News

July 31, 2021

Lonza positions collagen as “key” to future of joint health market

Life sciences

NutritionInsight speaks with Lindsey Toth, associate director of product management at DFS & Ingredients, Lonza Capsules & Health Ingredients.

July 31, 2021

Novo Holdings co-leads Hemab’s US$ 55M Series A to advance next generation therapeutics for bleeding and thrombosis disorders

Life sciences

The company was created in 2020 by Novo Seeds, which worked closely with the founders to develop a commercially attractive business plan to maximise the potential of Hemab’s promising technology platform.

July 31, 2021

BD acquires Tepha to drive new innovations in soft tissue repair and regeneration

Life sciences

BD (Becton, Dickinson and Company) announced today it has acquired Tepha, Inc., a leading developer and manufacturer of a proprietary resorbable polymer technology.

Send this to a friend